Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 29.8 USD 0.71% Market Closed
Market Cap: 1.7B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

AGIO Price Targets Summary
Agios Pharmaceuticals Inc

Wall Street analysts forecast AGIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGIO is 56.44 USD with a low forecast of 38.38 USD and a high forecast of 77.7 USD.

AGIO Lowest Forecast
Wall Street Target
38.38 USD
29% Upside
AGIO Average Forecast
Wall Street Target
56.44 USD
89% Upside
AGIO Highest Forecast
Wall Street Target
77.7 USD
161% Upside
Lowest
Price Target
38.38 USD
29% Upside
Average
Price Target
56.44 USD
89% Upside
Highest
Price Target
77.7 USD
161% Upside
Agios Pharmaceuticals Inc Competitors:
Price Targets
1167
Jacobio Pharmaceuticals Group Co Ltd
53% Downside
TSHA
Taysha Gene Therapies Inc
150% Upside
NBIX
Neurocrine Biosciences Inc
32% Upside
BONEX
Bonesupport Holding AB
68% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
53% Downside
TSHA
Taysha Gene Therapies Inc
150% Upside
NBIX
Neurocrine Biosciences Inc
32% Upside
BONEX
Bonesupport Holding AB
68% Upside
UTHR
United Therapeutics Corp
30% Upside
RLAY
Relay Therapeutics Inc
496% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
36% Upside
068270
Celltrion Inc
59% Upside

Revenue
Forecast

Revenue Estimate
Agios Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Agios Pharmaceuticals Inc's revenue is -8%. The projected CAGR for the next 3 years is 107%.

-8%
Past Growth
107%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Agios Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Agios Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

See Also

Summary
AGIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
AGIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AGIO stock valuation using valuation multiples.
Wall Street Estimates
AGIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AGIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AGIO's stock price target?
Price Target
56.44 USD

According to Wall Street analysts, the average 1-year price target for AGIO is 56.44 USD with a low forecast of 38.38 USD and a high forecast of 77.7 USD.

What is Agios Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
107%

For the last 8 years the compound annual growth rate for Agios Pharmaceuticals Inc's revenue is -8%. The projected CAGR for the next 3 years is 107%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.